20.38 USD
+0.53 (+2.67%)
20.38 USD
0 (0%)
Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 190 industry peers in the Pharmaceuticals industry. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PCRX has a bad growth rate and is valued cheaply. With these ratings, PCRX could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
- PCRX had positive earnings in the past year.
- PCRX had a positive operating cash flow in the past year.
- Of the past 5 years PCRX 4 years were profitable.
- In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
- PCRX has a better Return On Assets (1.65%) than 81.05% of its industry peers.
- PCRX has a Return On Equity of 2.95%. This is amongst the best in the industry. PCRX outperforms 82.11% of its industry peers.
- PCRX's Return On Invested Capital of 3.63% is amongst the best of the industry. PCRX outperforms 81.58% of its industry peers.
- PCRX had an Average Return On Invested Capital over the past 3 years of 4.30%. This is significantly below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- PCRX has a better Profit Margin (2.99%) than 79.47% of its industry peers.
- With an excellent Operating Margin value of 8.88%, PCRX belongs to the best of the industry, outperforming 81.05% of the companies in the same industry.
- In the last couple of years the Operating Margin of PCRX has grown nicely.
- With an excellent Gross Margin value of 79.17%, PCRX belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
- In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
- The number of shares outstanding for PCRX has been reduced compared to 1 year ago.
- Compared to 5 years ago, PCRX has more shares outstanding
- Compared to 1 year ago, PCRX has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 1.84 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- PCRX has a Altman-Z score (1.84) which is in line with its industry peers.
- PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 3.03, PCRX belongs to the best of the industry, outperforming 90.53% of the companies in the same industry.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.52, PCRX is doing worse than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.84 |
ROIC/WACC0.46
WACC7.83%
2.3 Liquidity
- A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
- PCRX has a better Current ratio (5.26) than 64.74% of its industry peers.
- PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.78, PCRX perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -16.85% in the last year.
- PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- The Earnings Per Share is expected to grow by 7.01% on average over the next years.
- PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.38% yearly.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 6.86, which indicates a rather cheap valuation of PCRX.
- Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 93.68% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.60. PCRX is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 5.86, the valuation of PCRX can be described as very cheap.
- Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 93.16% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 25.83. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.86 | ||
| Fwd PE | 5.86 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 96.32% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, PCRX is valued cheaply inside the industry as 96.32% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.06 | ||
| EV/EBITDA | 5.88 |
4.3 Compensation for Growth
- The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.49
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.86 and the Price/Book (PB) ratio is 1.21.